With the PDUFA date for its capsaicin pain patch Qutenza (capsaicin 179 mg) rapidly approaching, NeurogesX Inc. gained a nice chunk of cash and squared away European rights to the product in a potential €105 million (US$145.5 million) deal with Astellas Pharma Inc. (BioWorld Today)

Adding itself to the short list of firms daring to brave the public markets this year, ImmunoGen Inc. aims to bolster its balance sheet with a public offering of 5 million shares priced at $7 each for $35 million in gross proceeds. (BioWorld Today)

Shares of Alexza Pharmaceuticals Inc. shot up 51 percent on the company's plans to acquire Symphony Allegro, the joint venture with Symphony Capital LLC that has funded development of three Staccato programs for the past three years. (BioWorld Today)

Vitae Pharmaceuticals Inc. is getting $42 million up front in an early stage deal with Boehringer Ingelheim GmbH aimed at the much-sought-after - though difficult - space of disease-modifying drugs against Alzheimer's disease. (BioWorld Today)